NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Heron Therapeutics, Inc. /de/ HRTX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$154.9M
▲ 7.4% vs FY2024
EPS · FY25
$-0.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-13.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 154.9M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 13 cents on every revenue dollar this year.
Per share
USD -0.12
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-1.6%
Net margin-13.0%
Return on assets-8.3%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+11.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.9%
+11.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years+106.2%
Change, 10 years—
The share count grew 106% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 255.9M
total assets, end of FY2025
Total assetsUSD 255.9M
EquityUSD 14.3M
CashUSD 28.6M
Current ratio2.48×
Equity funds 6% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.1
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.1
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
Net income $B
−0.0
−0.0
−0.1
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.12
−0.09
−0.80
−1.67
−2.24
−2.50
−2.50
−2.44
−3.65
−4.56
−2.95
−2.87
−3.42
−1.91
−1.96
−0.19
−0.31
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
−399.4
−140.5
−71.0
−52.9
−71.4
−359.4
−357.5
−107.7
−115.7
−91.6
−69.1
−138.4
−181.1
−147.6
Shares out B
0.19
0.15
0.15
0.12
0.10
0.09
0.09
0.08
0.06
0.00
0.04
0.03
0.02
0.02
0.20
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed